P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy
Titel:
P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy
Auteur:
Ciardiello, D. Famiglietti, V. Napolitano, S. Terminiello, M. Borrelli, C. Vitiello, P. Pietrantonio, F. Avallone, A. Normanno, N. Maiello, E. Latiano, T. Cremolini, C. Santabarbara, G. Pinto, C. Santini, D. Esposito, L. Di Liello, A. Troiani, T. Ciardiello, F. Martinelli, E. Martini, G.